ProKidney Corp.

Mr. Richard  Williams

Senior Vice President of Information Technology

Dr. Aparna  Sahoo M.D.

Vice President & Head of Global Clinical Development

Ms. Carla  Poulson

Chief People Officer

Mr. Todd C. Girolamo Esq., J.D., M.B.A.

Chief Legal Officer & Secretary

Dr. Timothy A. Bertram D.V.M., Ph.D.

Founder

Dr. Bruce  Culleton M.D.

Chief Executive Officer & Director

Mr. James  Coulston CPA

Chief Financial Officer

Dr. Joseph M. Stavas M.D., M.P.H.

Senior Vice President of Interventional Procedures & Patient Safety

Dr. Darin J. Weber Ph.D.

Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access

Mr. Nikhil L. Pereira-Kamath

Chief Business Officer

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentially preserve kidney function in patients with type 2 diabetes and advanced CKD.

ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.

WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Morgan Stanley 22nd Annual Global Healthcare Conference, being held in New York, NY on September 4-6, 2024.

ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

WINSTON-SALEM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) --  ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the second quarter ended June 30, 2024.

ProKidney Reports Business Updates and Second Quarter 2024 Financial Results

Top-ranked stocks Wingstop (WING), Burlington Stores (BURL) and Prokidney CP (PROK) are likely to beat on the bottom line in their upcoming releases.

Play Likely Earnings Beat With 3 Top-Ranked Stocks

WINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an underwritten public offering and a concurrent registered direct offering of 53,719,009 shares of its Class A ordinary shares at a price of $2.42 per share, before applicable underwriting discounts and commissions. In addition, the underwriters will have a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company. The public offering and the concurrent registered direct offering are each expected to close on or about June 13, 2024, subject to customary closing conditions. The underwritten public offering is not contingent on the closing of the concurrent direct offering, and the concurrent direct offering is not contingent on the closing of the underwritten public offering.

ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

ProKidney Corp.PROK

ProKidney Corp.
PROK